Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.

Bone marrow transplantation is regarded as the most effective immunotherapy for hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of histone deacetylases (HDACs) is closely related to the occurrence and development of hematological cancer. Recent studies suggested that HDACs might play a critical role in initiating anti-cancer immune response or enhancing anti-cancer immunotherapy. Besides, combining HDAC inhibition and immunotherapy could prevent immunotherapy resistance in some degree and reach an extended treatment window. This review summarized the relationship between HDACs and immune and described the current understanding of HDACs in immunotherapy for hematologic cancer. HDACs may play a critical role in initiating anti-tumor immune response or enhancing anti-cancer immunotherapy. Combining HDACI and immunotherapy can prevent immunotherapy resistance in some degree and reach an extended treatment window. [Display omitted] •Targeting HDACs could initiate anti-tumor immune response in the hematologic cancer. •Targeting HDACs could enhance anti-tumor immunotherapy for hematologic cancer. •Combining HDACIs and immunotherapy could reach an extended treatment window. [ABSTRACT FROM AUTHOR]